Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;25(9):2553-2560.
doi: 10.1111/dom.15140. Epub 2023 May 29.

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Sue D Pedersen  1 , Francesco Giorgino  2 , Guillermo Umpierrez  3 , Vivian T Thieu  4 , Angel Rodríguez  4 , Claudia Nicolay  4 , Laura Fernández Landó  4 , Chrisanthi A Karanikas  4 , Jacek Kiljanski  4
Affiliations

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Sue D Pedersen et al. Diabetes Obes Metab. 2023 Sep.

Abstract

Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg).

Materials and methods: HbA1c and body weight data at 40 weeks (SURPASS-1, -2 and -5) and 52 weeks (SURPASS-3 and -4) were analysed by trial.

Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%-99%, 98%-99% and 94%-99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%-94%, 88%-95% and 88%-97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS-2, -3, -4 (all doses) and -5 (tirzepatide 5 mg only).

Conclusions: In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS-2, SURPASS-3 and SURPASS-4, suggesting that both weight-independent and weight-dependent mechanisms are responsible for the tirzepatide-induced improvement in glycaemic control.

Keywords: body weight; glycaemic control; tirzepatide; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. US Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes in clinical trials, treatment proved more effective than other therapies evaluated [Press release]. 2022 https://www.fda.gov/news-events/press-announcements/fda-approves-novel-d... Last accessed: January 9, 2023.
    1. Mounjaro [Press Release]. European Commission Grants Marketing Authorisation for Lilly's Mounjaro® (Tirzepatide), the First GIP and GLP-1 Receptor Agonist for Adults with Type 2 Diabetes in Europe. Eli Lilly and Company; 2022 https://www.lillyeu.com/story/european-commission-grants-marketing-autho.... Last accessed: January 9, 2023.
    1. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
    1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
    1. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598.

Publication types

LinkOut - more resources